NIH partners with Framingham biotech to develop cancer drug

National Institutes of Health partners with Framingham biotech Berg to develop cancer drug – Boston Business Journal A Framingham-based company’s artificial intelligence-developed cancer drug has caught the attention of the federal government, which has plans to conduct preclinical trials to help speed the drug to market. The technology and methodology were developed by Berg using computer algorithms and artificial intelligence, which analyzed large amounts of tumor data and pointed to a drug that could force cancer cells to die. “What the AI platform has done is helped us to develop this drug by understanding that the key hallmark of cancer is the cancer metabolism,” said Niven Narain, president, chief technology officer and co-founder of Berg, which is entirely backed and co-founded by Silicon Valley real estate billionaire Carl E. Berg.…

Link to Full Article: NIH partners with Framingham biotech to develop cancer drug

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!